Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

被引：6
|
作者：
Jaeger, Ulrich
Worel, Nina
McGuirk, Joseph
Riedell, Peter A.
Fleury, Isabelle
Borchmann, Peter
Du, Yan
Abdelhady, Ahmed M.
Han, Xia
Martinez-Prieto, Marcela
Waller, Edmund K.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA
[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Hop Maisonneuve Rosemont, Dept Med Specialisee, Hematooncol, Montreal, PQ, Canada
[5] Klinikum Univ Koln, Cologne, Germany
[6] Novartis Pharma AG, Shanghai, Peoples R China
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
[8] Emory Clin, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19537
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
    Hideki Goto
    Shinichi Makita
    Koji Kato
    Kota Tokushige
    Taizo Fujita
    Koichi Akashi
    Koji Izutsu
    Takanori Teshima
    International Journal of Clinical Oncology, 2020, 25 : 1736 - 1743
  • [22] Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
    Goto, Hideki
    Makita, Shinichi
    Kato, Koji
    Tokushige, Kota
    Fujita, Taizo
    Akashi, Koichi
    Izutsu, Koji
    Teshima, Takanori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (09) : 1736 - 1743
  • [23] Safety and Efficacy of Tisagenlecleucel Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and No Evidence of Active Disease Following Bridging Chemotherapy in the JULIET Trial
    Bishop, Michael R.
    Maziarz, Richard Thomas T.
    Waller, Edmund K.
    del Corral, Christopher
    Tiwari, Ranjan
    Anak, Ozlem
    Awasthi, Rakesh
    Romanov, Vadim V.
    Schuster, Stephen J.
    BLOOD, 2018, 132
  • [24] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Sehn, L. H.
    McMillan, A.
    Matasar, M. J.
    Flowers, C. R.
    Kamdar, M.
    Hertzberg, M.
    Assouline, S.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Croft, B.
    Herrera, A. F.
    Hirata, J.
    Cheng, J.
    Ku, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
  • [25] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
  • [26] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [27] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [28] Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.
    Yang, Hongbo
    Qi, Cynthia Zhengyun
    Dalal, Anand
    Bollu, Vamsi
    Zhang, Jie
    Zhang, Su
    Lim, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [30] Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel
    Andreadis, C.
    Tam, C. S.
    Borchmann, P.
    Jaeger, U.
    McGuirk, J. P.
    Holte, H.
    Waller, E. K.
    Jaglowski, S.
    Bishop, M. R.
    Foley, S. R.
    Westin, J. R.
    Fleury, I
    Ho, P. J.
    Mielke, S.
    Teshima, T.
    Salles, G. A.
    Schuster, S. J.
    Bachanova, V
    Maziarz, R. T.
    Besien, K., V
    Izutsu, K.
    Wagner-Johnston, N. D.
    Kato, K.
    Corradini, P.
    Tiwari, R.
    Awasthi, R.
    Lawniczek, T.
    Eldjerou, L. K.
    Kersten, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 62 - 63
12345